Compare Exelixis Inc. Common Stock (EXEL) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Exelixis Inc. Common Stock vs Tilray Brands Inc — how do they compare? Exelixis Inc. Common Stock trades at $59.73 (market cap $14.62B), while Tilray Brands Inc trades at $3.44 (market cap $530.54M). The key difference: Exelixis Inc. Common Stock is far larger — about 27.6× Tilray Brands Inc's market cap, and Exelixis Inc. Common Stock is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Exelixis Inc. Common Stock for 0 Days and Tilray Brands Inc for 31 Days on average.
| EXEL | TLRY | |
|---|---|---|
Market Cap | $14.62B | $530.54M |
Volume | 2,684,957 | 9,099,075 |
Sector | Health | Health |
52-Week High | $59.13 | $21.00 |
52-Week Low | $34.54 | $3.57 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $13.95B | $684.46M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TLRY trades at $3.465, down 6.73% on the day and near 52-week lows, reflecting persistent bearish sentiment. The stock shows weak technical momentum with oversold RSI readings but faces fundamental challenges including consecutive quarterly earnings misses, negative profit margins, and declining revenue growth. Recent news highlights the company's struggles with profitability despite record annual revenue, with shares down over 50% year-to-date as investors question the cannabis company's path to sustainable growth.
TLRY presents a high-risk opportunity with significant downside protection from its low P/B ratio of 0.33, but requires substantial operational improvement to justify investment. The bullish case hinges on potential marijuana reform catalysts and BrewDog integration progress, while risks include ongoing losses, competitive pressures, and execution challenges in a volatile regulatory environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Exelixis Inc. Common Stock
Exelixis develops and commercializes medicines for cancer. Its research focuses on targeted therapies for oncology.
Read more on EXEL →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
